The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Laparoscopic Antireflux Surgery vs Esomeprazole Treatment for Chronic GERD: The LOTUS Randomized Clinical Trial
Abstract
CONTEXT: Gastroesophageal reflux disease (GERD) is a chronic, relapsing disease with symptoms that have negative effects on daily life. Two treatment options are long-term medication or surgery. OBJECTIVE: To evaluate optimized esomeprazole therapy vs standardized laparoscopic antireflux surgery (LARS) in patients with GERD. DESIGN, SETTING, AND PARTICIPANTS: The LOTUS trial, a 5-year exploratory randomized, open, parallel-group trial conducted in academic hospitals in 11 European countries between October 2001 and April 2009 among 554 patients with well-established chronic GERD who initially responded to acid suppression. A total of 372 patients (esomeprazole, n = 192; LARS, n = 180) completed 5-year follow-up. Interventions Two hundred sixty-six patients were randomly assigned to receive esomeprazole, 20 to 40 mg/d, allowing for dose adjustments; 288 were randomly assigned to undergo LARS, of whom 248 actually underwent the operation. MAIN OUTCOME MEASURE: Time to treatment failure (for LARS, defined as need for acid suppressive therapy; for esomeprazole, inadequate symptom control after dose adjustment), expressed as estimated remission rates and analyzed using the Kaplan-Meier method. RESULTS: Estimated remission rates at 5 years were 92% (95% confidence interval [CI], 89%-96%) in the esomeprazole group and 85% (95% CI, 81%-90%) in the LARS group (log-rank P = .048). The difference between groups was no longer statistically significant following best-case scenario modeling of the effects of study dropout. The prevalence and severity of symptoms at 5 years in the esomeprazole and LARS groups, respectively, were 16% and 8% for heartburn (P = .14), 13% and 2% for acid regurgitation (P < .001), 5% and 11% for dysphagia (P < .001), 28% and 40% for bloating (P < .001), and 40% and 57% for flatulence (P < .001). Mortality during the study was low (4 deaths in the esomeprazole group and 1 death in the LARS group) and not attributed to treatment, and the percentages of patients reporting serious adverse events were similar in the esomeprazole group (24.1%) and in the LARS group (28.6%). CONCLUSION: This multicenter clinical trial demonstrated that with contemporary antireflux therapy for GERD, either by drug-induced acid suppression with esomeprazole or by LARS, most patients achieve and remain in remission at 5 years. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00251927.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Methods for Rates and Proportions
Fleiss, J. L., Levin, B., & Paik, M. C. (2003) · Wiley Series in Probability and Statistics · doi:10.1002/0471445428 · Cited by 18,646
Long-term Proton Pump Inhibitor Therapy and Risk of Hip Fracture
Yang, Y.-X., Lewis, J. D., Epstein, S., & Metz, D. C. (2006) · JAMA · doi:10.1001/jama.296.24.2947 · Cited by 1,214
Spechler, S. J., Lee, E., Ahnen, D., Goyal, R. K., Hirano, I., Ramirez, F., Raufman, J.-P., Sampliner, R., Schnell, T., Sontag, S., et al. (2001) · JAMA · doi:10.1001/jama.285.18.2331 · Cited by 909
Miner, P. (2003) · The American Journal of Gastroenterology · doi:10.1016/j.amjgastroenterol.2003.09.053 · Cited by 442
Esomeprazole (40 Mg) Compared With Lansoprazole (30 Mg) in The Treatment of Erosive Esophagitis
Castell, D. O., Kahrilas, P. J., Richter, J. E., Vakil, N. B., Johnson, D., Zuckerman, S., Skammer, W., & Levine, J. G. (2002) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(01)04094-1 · Cited by 436
Camilleri, M., Dubois, D., Coulie, B., Jones, M., Kahrilas, P. J., Rentz, A. M., Sonnenberg, A., Stanghellini, V., Stewart, W. F., Tack, J., et al. (2005) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(05)00153-9 · Cited by 384
Targownik, L. E., Lix, L. M., Leung, S., & Leslie, W. D. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.11.014 · Cited by 253
Kulig, M., Leodolter, A., Vieth, M., Schulte, E., Jaspersen, D., Labenz, J., Lind, T., Meyer‐Sabellek, W., Malfertheiner, P., Stolte, M., et al. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01770.x · Cited by 248
Self-citationGralnek, I. M., Dulai, G. S., Fennerty, M. B., & Spiegel, B. M. R. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.09.013 · Cited by 198
Lundell, L., Attwood, S., Ell, C., Fiocca, R., Galmiche, J.-P., Hatlebakk, J., Lind, T., & Junghard, O. (2008) · Gut · doi:10.1136/gut.2008.148833 · Cited by 196
Self-citationMahon, D., Rhodes, M., Decadt, B., Hindmarsh, A., Lowndes, R., Beckingham, I., Koo, B., & Newcombe, R. G. (2005) · British Journal of Surgery · doi:10.1002/bjs.4934 · Cited by 182
Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily
Hatlebakk, Katz, Kuo, & Castell (1998) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1998.00426.x · Cited by 181
Meta-Analysis of Randomized Clinical Trials Comparing Open and Laparoscopic Anti-Reflux Surgery
Peters, M. J., Mukhtar, A., Yunus, R. M., Khan, S., Pappalardo, J., Memon, B., & Memon, M. A. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.176 · Cited by 164
hss, K. R., Lind, T., & Wilder‐Smith, C. H. (2004) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-004-0804-6 · Cited by 153
Self-citationLong-Term Outcomes After Laparoscopic Antireflux Surgery
Oelschlager, B. K., Quiroga, E., Parra, J. D., Cahill, M., Polissar, N. L., & Pellegrini, C. A. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01606.x · Cited by 139
Systematic review: the impact of gastro‐oesophageal reflux disease on work productivity
Wahlqvist, P., Reilly, M. C., & Barkun, A. N. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.02996.x · Cited by 132
Grant, A., Wileman, S., Ramsay, C. R., Mowat, N. A. G., Krukowski, Z. H., Heading, R. C., Thursz, M. R., Campbell, M., & and the REFLUX Trial Group (2008) · BMJ · doi:10.1136/bmj.a2664 · Cited by 108
Edwards, S. J., Lind, T., & Lundell, L. R. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03074.x · Cited by 96
Self-citationAdverse effects of proton pump inhibitors
Lodato, F., Azzaroli, F., Turco, L., Mazzella, N., Buonfiglioli, F., Zoli, M., & Mazzella, G. (2010) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2009.11.004 · Cited by 94
Standardization of Surgical Technique in Antireflux Surgery: The LOTUS Trial Experience
Attwood, S. E., Lundell, L. R., Ell, C., Galmiche, J., Hatlebakk, J., Fiocca, R., Lind, T., Eklund, S., Junghard, O., & The LOTUS Trial Group (2008) · World Journal of Surgery · doi:10.1007/s00268-007-9409-4 · Cited by 87
Self-citationFiocca, R., Mastracci, L., Engström, C., et al. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.631 · Cited by 60
Self-citationHip Fracture and Proton Pump Inhibitor Therapy: Balancing the Evidence for Benefit and Harm
Moayyedi, P., & Cranney, A. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.02031.x · Cited by 29
Cited by
for the SIF-AIGO-FIMMG Group, Scarpignato, C., on behalf of the Italian Society of Pharmacology, T. I. A. O. H. G., Gatta, L., Zullo, A., & Blandizzi, C. (2016) · BMC Medicine · doi:10.1186/s12916-016-0718-z · Cited by 469
Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors
Sifrim, D., & Zerbib, F. (2012) · Gut · doi:10.1136/gutjnl-2011-301897 · Cited by 346
Management of Gastroesophageal Reflux Disease
Gyawali, C. P., & Fass, R. (2018) · Gastroenterology · doi:10.1053/j.gastro.2017.07.049 · Cited by 346
Symptomatic reflux disease: the present, the past and the future
Boeckxstaens, G., El-Serag, H. B., Smout, A. J. P. M., & Kahrilas, P. J. (2014) · Gut · doi:10.1136/gutjnl-2013-306393 · Cited by 275
Zhang, D., Liu, S., Li, Z., & Wang, R. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2074535 · Cited by 258
Metadata
- Authors
- Galmiche, J.-P., Hatlebakk, J., Attwood, S., Ell, C., Fiocca, R., Eklund, S., Långström, G., Lind, T., Lundell, L., & LOTUS Trial Collaborators, F. T.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2011-05-18
- Volume
- 305
- Issue
- 19
- Pages
- 1969-77
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2030314050
- Cited by
- 448
- References
- 22
- FWCI
- 40.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.